We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| 4basebio Plc | LSE:4BB | London | Ordinary Share | GB00BMCLYF79 | ORD EUR1.00 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,405.00 | 1,380.00 | 1,430.00 | 1,430.00 | 1,405.00 | 1,405.00 | 294 | 08:00:19 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 335k | -5.15M | -0.4180 | -33.61 | 173.09M |
Hot Features
Premium
TIDM4BB
14 June 2023
4basebio PLC
("4basebio" or the "Company")
Annual General Meeting 2023 ("AGM")
4basebio Plc (AIM: 4BB), an innovation driven biotechnology company enabling
and accelerating development of advanced therapy medicinal products (ATMPs)
through its high performant synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform announces that all of the resolutions
proposed at its Annual General Meeting held earlier today were duly passed.
The Company also wishes to again draw attention to the investor meeting being
held on 16 June 2023, through the Investor Meet Company platform at 10.00am.
Investors can sign up to Investor Meet Company for free and register interest
here:
https://www.investormeetcompany.com/register-investor
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396
7943
Heikki Lanckriet
Nominated Adviser +44 (0)20 7213 0880
Cairn Financial Advisers LLP
Jo Tuner / Sandy Jamieson
Broker +44 (0)20
7220 0500
finnCap Ltd
Geoff Nash/Richard Chambers/Charlotte Sutcliffe
Lionsgate Communications (Media Enquiries) +44 (0)77 91892509
Jonathan Charles
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focussed
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high performant synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company' objective is to become a
market leader in the manufacture and supply of high quality synthetic DNA
products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients. The company is offering GMP compliant DNA starting
materials suitable for use in AAV viral vector production as well as mRNA
vaccine and therapeutics production.
END
(END) Dow Jones Newswires
June 14, 2023 07:52 ET (11:52 GMT)
1 Year 4basebio Chart |
1 Month 4basebio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
